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CirrhosisAbstract Background: Norfloxacin is the most commonly used agent for the prophylaxis against
spontaneous bacterial peritonitis (SBP) in patients with liver cirrhosis. Rifaximin, another broad
spectrum antibiotic, is used for the treatment of traveler’s diarrhea and hepatic encephalopathy.
Objective: We aimed to test the efficacy of rifaximin versus norfloxacin for prevention of SBP in
patients with hepatitis C virus (HCV)-related liver cirrhosis.
Patients and methods: 86 patients with HCV-related liver cirrhosis and ascites were enrolled and
divided into two groups of matching age, sex and Child–Pugh class. Group I was given norfloxacin
400 mg/day as single dose, and group II rifaximin 1200 mg/day in three divided doses. They were
followed for up to one year. Study endpoints were SBP, hepatocellular carcinoma, compliance fail-
ure, death, or liver transplantation.
Results: More than 70% of patients received the antimicrobial as primary prophylaxis and the rest
were given secondary prophylaxis against SBP. The mean follow-up period was 10.16
± 2.64 months for norfloxacin and 10.26 ± 2.32 months for rifaximin (p= 0.863). Although sta-
tistically insignificant (p= 0.265), patients on rifaximin developed fewer episodes of SBP than those
on norfloxacin (4.7% vs. 14%). Also, the infection-free duration before SBP was longer (p= 0.129)
with rifaximin than norfloxacin (9.5 vs. 5.0 months). Rifaximin significantly reduced the rate of new
compared to past episodes of SBP by 20.9% (p= 0.007) vs. 13.9% for norfloxacin (p= 0.112).
Overall survival was equal in both groups. Patients adhered to therapy regimen of norfloxacin
for significantly longer time than rifaximin (p= 0.010).
Conclusion: Rifaximin is – at least – as good as norfloxacin. It seems to be an appropriate alterna-
tive for long-term primary and secondary prophylaxis of SBP in cirrhotic patients with ascites.
Modification of dose regimen should be considered to improve patient’s compliance to rifaximin.
 2015 The Authors. Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).ity, 165
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Spontaneous bacterial peritonitis (SBP) is a common bacterial
infection in patients with cirrhosis and ascites, occurring in up
to 30% of patients with cirrhosis, and having an estimated in-
hospital mortality rate of 20%. Half the episodes of SBP are
present at the time of hospital admission, while the rest are
acquired during hospitalization.1–3 Patients with SBP may pre-
sent with a wide spectrum of manifestations, ranging from
local symptoms and/or signs of peritonitis (abdominal pain,
abdominal tenderness, vomiting, diarrhea, ileus) with or with-
out signs of systemic inflammation (hyper- or hypothermia,
altered white blood cell count, tachycardia, and/or tachypnea,
shock); to unexplained renal failure or unexplained worsening
of liver function and hepatic encephalopathy. At the very end
of this spectrum, however, lies a good percentage of patients
with SBP who are asymptomatic.4,5 Hence, the diagnosis of
SBP is based mainly on diagnostic paracentesis.6
Ascitic fluid cell analysis usually shows an increased num-
ber of neutrophils, which must reach a count of at least 250/
mm3 in order to confirm the diagnosis of SBP. If ascitic fluid
culture is positive (which is the case only in 40% of patients
with proved SBP), the most common pathogens include
Gram-negative bacteria (usually Escherichia coli) and Gram-
positive cocci (mainly streptococcus species and entero-
cocci).1–3 Ascites culture, however, might be negative in up
to 60% of patients who have increased ascites neutrophil
count, a category also known as ‘‘culture-negative SBP”. A
third category of patients might have ‘‘bacterascites”, in which
cultures are positive but ascitic neutrophil count is less than
250/mm3. In both categories the clinical presentation is similar
to classic SBP, and patients should be treated in a similar man-
ner.6 Small intestinal dysmotility and bacterial overgrowth,
which are commonly encountered in patients with liver cirrho-
sis, are the major contributing factors for inviting enteric bac-
terial ‘‘translocation” from the intestinal lumen to mesenteric
lymph nodes and other extra intestinal sites, resulting in
SBP.7–9 In addition, several humoral and cell-mediated abnor-
malities of the immune system increase the susceptibility for
bacterial infections in cirrhotic patients, particularly for
SBP.10,11
When first described, the mortality from SBP exceeded
90%, but it has been reduced to approximately 20% with early
diagnosis and treatment.12,13 Typical treatment of SBP
includes empirical antibiotic therapy, which must be initiated
immediately after its diagnosis, without awaiting the results
of ascitic fluid culture.3,6 Cefotaxime, a third-generation
cephalosporin, is the drug of choice with a recommended dose
of 6 g/day for a minimum of 5 days, because it covers most
causative organisms and has high ascitic fluid concentra-
tions.14,15 Ciprofloxacin, given either for 7 days intravenously
or for 2 days intravenously followed by 5 days orally, results
in a similar SBP resolution rate and achieves hospital survival
comparable with cefotaxime.16
Cirrhotic patients with low ascitic fluid protein concentra-
tion (<1.5 g/dl) and/or high serum bilirubin levels are at high
risk of developing a first episode of SBP.17–19 Also, patients
who have survived an episode of SBP were proved to have a
1-year recurrence rate of about 70%.13 Studies have evaluated
long-term prophylaxis in patients with or without prior history
of SBP. The ideal prophylactic agent should be safe,affordable, and effective at decreasing the amounts of patho-
genic microorganisms from the gut while preserving the pro-
tective flora (selective intestinal decontamination).
Norfloxacin is a quinolone with limited absorption from the
gastrointestinal tract which has antibacterial activity against
Gram-negative but not against Gram-positive cocci or anaero-
bic bacteria. It is the most commonly used approach for the
prophylaxis of SBP in patients with ascites, at a dose of
400 mg/day orally.20–22 Several guidelines (including those of
the American Association for the Study of Liver Diseases;
AASLD) suggested the long-term prophylactic use of nor-
floxacin or trimethoprim/sulfamethoxazole against SBP.23
However, given the cost and unavoidable hazard of developing
resistant organisms, the use of prophylactic antibiotics is firmly
restricted to patients at high risk for developing SBP. Never-
theless, recent years have witnessed a significant change in
the epidemiology of bacterial infections in cirrhosis, with an
increasing incidence of quinolone-resistant bacteria.2,24,25
One study has shown that a considerable number of infections
following acute gastrointestinal hemorrhage were caused by
Gram-positive bacteria, which was likely related to invasive
procedures used in these patients. In addition, 30% of the iso-
lated Gram-negative bacteria were resistant to quinolones and
30% were resistant to trimethoprim–sulfamethoxazole.2
Another trial tested norfloxacin for primary prophylaxis
against SBP in 109 patients with cirrhosis and ascitic fluid total
protein level <15 g/L or serum bilirubin level >2.5 mg/dl.
SBP was reduced at the expense of more resistance of gut flora
to norfloxacin in that group.26
Rifaximin is another broad spectrum antibiotic with only
trivial absorption from the gut. It acts by inhibiting bacterial
RNA synthesis. Since the mid-80s, rifaximin has been exten-
sively investigated for its anti-diarrheal properties, and since
2004 it has received approval from the American Food and
Drug Administration (FDA) for the treatment of traveler’s
diarrhea, followed by approval for treatment of hepatic
encephalopathy in 2010.27 Till now, rifaximin has demon-
strated broad spectrum antibacterial activity against Gram-
positive and Gram-negative organisms, both aerobes and
anaerobes, with low risk of introducing bacterial resis-
tance.28–30 The aim of this study was to test the efficacy of
rifaximin in comparison with norfloxacin for the prevention
of spontaneous bacterial peritonitis in patients with HCV-
related liver cirrhosis and ascites.
2. Patients and methods
A total of 86 consecutive patients with decompensated HCV-
related liver cirrhosis (Child–Pugh classes B and C) who were
admitted to the Hepatology and Gastroenterology Unit, Med-
ical Research Institute, Alexandria University, during the per-
iod from January 2012 till December 2013 were enrolled in the
study. Patients were selected for long-term antibiotic prophy-
laxis according to the recommendations (Evidence class I, level
A) of the AASLD for participating in this study.23 Patients
who proved to have survived a previous episode of SBP were
given secondary prophylaxis. Also, high risk patients with
baseline ascitic fluid protein <1.5 g/dl along with impaired
renal function (creatinine P1.2, blood urea nitrogen
P25 mg/dl or serum sodium level 6130 mEq/L) or patients
with liver failure (Child score P9 and serum bilirubin
Rifaximin: A reasonable alternative for norfloxacin 221P3 mg/dl) with no proof of previous attack of SBP were
included for primary prophylaxis. Exclusion criteria were eti-
ologies of liver cirrhosis other than HCV, recent abdominal
surgery (within past 6 months), abdominal malignancy
(including hepatocellular carcinoma), portal vein thrombosis,
splenectomy and hypersensitivity to norfloxacin or rifaximin.
Patients were divided into two groups of matching age, sex
and Child–Pugh class. Group I (43 patients) were given nor-
floxacin 400 mg/day as a single dose, and group II (43 patients)
were given rifaximin 1200 mg/day in three divided doses.
Diagnosis of cirrhosis was based on clinical findings
(ascites, splenomegaly, lower limb edema and/or esophageal
varices by upper gastrointestinal endoscopy), imaging (abdom-
inal ultrasound) and laboratory findings. HCV infection was
proved by Real Time-Polymerase Chain Reaction (RT-
PCR). The severity of cirrhosis was graded according to the
Child–Pugh’s classification. Presence of ascites was confirmed
by abdominal ultrasound, and baseline diagnostic ascitic fluid
protein analysis was performed to identify high risk patients.
Patients were followed for up to one year. Other study end-
points were developing SBP (or any other infection requiring
systemic antibiotic treatment), emergence of hepatocellular
carcinoma, compliance failure, death, or liver transplantation.
The term ‘‘overall survival” referred to continuing the one-year
study duration without facing any of the study endpoints.
Monthly planned follow-up visits were scheduled to record
treatment compliance, as well as diagnose and manage compli-
cations. Patients lost to follow-up or who discontinued pro-
phylaxis without permission for more than seven days were
designated as ‘‘compliance failure” on the day of last visit or
last dose taken. Patients requiring alternative intervention
for complications (hepatic encephalopathy, variceal bleeding
or hepatorenal syndrome) were managed according to the
guidelines of the AASLD.23 During an active variceal bleeding
attack, oral prophylaxis was discontinued and the only antibi-
otic given to patients of both groups to prevent bacterial infec-
tions was Ceftriaxone (1 g/day for seven days). During an
episode of overt hepatic encephalopathy, the planned oral
antibiotic prophylaxis was continued without change (via
nasogastric tube if necessary), and only the concomitant use
of lactulose was permitted. Hepatorenal syndrome was man-
aged by albumin infusion (10–20 grams/day) plus octreotide
with a target dose of 200 lgrams subcutaneously 3 times per
day, and midodrine titrated up to a maximum of 12.5 mg
orally 3 times/day. If SBP was suspected, diagnostic paracente-
sis of ascitic fluid sample and microbiological culture were
done to confirm the diagnosis. SBP was defined as the presence
of a polymorphonuclear count in ascitic fluid P250/ml irre-
spective of the result of the microbiological culture. Patients
with proved SBP were censored from the study on the day of
confirmed diagnosis.
3. Statistical analysis
Data were analyzed using IBM SPSS software package version
20.0. Qualitative data were described using number and per-
cent. Quantitative data were described using mean and stan-
dard deviation for normally distributed data while
abnormally distributed data were expressed using median,
minimum and maximum. Comparison between different
groups regarding categorical variables was tested usingChi-square test. When more than 20% of the cells have
expected count less than 5, correction for chi-square was con-
ducted using Fisher’s Exact test. For normally distributed
data, comparison between the two studied groups was done
using independent t-test while for abnormally distributed data,
comparison was done using Mann Whitney test. Significance
of the obtained results was judged at the 5% level. Kaplan–
Meier analysis was used to examine the cumulative probability
of overall survival and patient’s compliance to therapy.31
4. Results
The baseline characteristics of the study population are sum-
marized in Table 1. A total of 86 patients with HCV-related
liver cirrhosis were included in the study. They were divided
into two groups (Norfloxacin versus Rifaximin group; 43
patients each) of matching age, sex and Child–Pugh class.
23.3% of patients in both groups were Child class B, while
76.7% were Child class C. All patients had ascites. More than
70% of patients received the antimicrobial agent as primary
prophylaxis against SBP, while the rest had previous history
of SBP and were given secondary prophylaxis, with no signif-
icant difference between the two groups. Also, baseline values
for liver profile parameters, renal function and ascitic fluid
albumin concentration were similar in both groups (p> 0.05).
4.1. Follow-up
The mean follow-up period of patients till occurrence of any of
the study endpoints was 10.16 ± 2.64 (range 3–12) months for
norfloxacin and 10.26 ± 2.32 (range 5–12) months for rifax-
imin, with no significant difference between both groups. Dur-
ing this period, patients on rifaximin developed fewer episodes
of hepatic encephalopathy (HE) than patients on norfloxacin
(4.7% and 9.3%, respectively). Also, when comparing the num-
ber of patients with past history of HE to those who developed
new episodes of HE during the study duration, rifaximin was
found to reduce the number of episodes by 11.6% versus
4.7% for norfloxacin. The difference, however, was not statisti-
cally significant in both occasions. The two groups had compa-
rable number of variceal bleeding episodes during the follow-up
period, and only one patient in each group developed hepatore-
nal syndrome. Four patient (9.3%) in the norfloxacin group
developed hepatocellular carcinoma versus 5 patients (11.6%)
in the rifaximin group, with no significant difference between
them, as demonstrated in Table 2. None of the patients under-
went liver transplantation during the study period.
4.2. Spontaneous bacterial peritonitis (SBP)
Patients who received rifaximin prophylaxis developed fewer
episodes of SBP than those on norfloxacin (4.7% vs. 14%,
respectively), with statistically nonsignificant difference. Also,
the duration before developing a new attack of SBP was longer
with rifaximin compared to norfloxacin patients (9.5 vs.
5.0 months, respectively). Additionally, rifaximin significantly
reduced the rate of new compared to past episodes of SBP
by 20.9% (p = 0.007), while the rate reduction with nor-
floxacin was only by 13.9% and not statistically significant
(p= 0.112), as demonstrated in Table 2 and Fig. 1. Cultures
of ascitic fluid from patients who developed new SBP were
Table 1 Comparison between the two groups according to baseline characteristics.
Norfloxacin (n= 43) Rifaximin (n= 43) p
Age (years) 50.3 ± 9.0 52.7 ± 8.5 0.425
Sex
Male 34 (79.1%) 34 (79.1%) 1.000
Female 9 (20.9%) 9 (20.9%)
Prophylaxis type
Primary (high risk) 31 (72.1%) 32 (74.4%) 0.808
Secondary (previous SBP) 12 (27.9%) 11 (25.6%)
Child–Pugh class
B 10 (23.3%) 10 (23.3%) 1.000
C 33 (76.7%) 33 (76.7%)
Child score 11.51 ± 2.06 11.47 ± 2.04 0.917
Ascites
Mild 8 (18.6%) 7 (16.3%) 0.823
Moderate/severe 35 (81.4%) 36 (83.7%)
Serum bilirubin (mg/dl) 2.9 ± 1.7 2.3 ± 1.0 0.192
Serum albumin (g/dl) 2.9 ± 0.4 2.8 ± 0.5 0.121
Prothrombin time (s) 17.1 ± 1.8 16.9 ± 2.0 0.324
Blood urea nitrogen (mg/dl) 23 (16–54) 24 (14–61) 0.533
Serum creatinine (mg/dl) 1.10 (0.70  3.10) 1.0 (0.70  3.10) 0.562
Serum sodium (mEq/L) 129.5 ± 7.3 130.0 ± 5.5 0.487
Ascitic fluid protein (g/dl) 0.9 ± 0.6 1.0 ± 0.5 0.253
SBP: spontaneous bacterial peritonitis. Qualitative data were expressed using number and percent and compared using Chi square test.
Normally distributed quantitative data were expressed in (Mean ± SD) and compared using t-student test. Abnormally distributed quantitative
data were expressed in Median (Min. – Max.) and compared using Mann Whitney test.
*Statistically significant at p 6 0.05.
Table 2 Comparison between the two groups according to follow-up events.
Norfloxacin (n= 43) Rifaximin (n= 43) p1
Hepatic encephalopathy
Past 6 (14.0%) 7 (16.3%) 0.763
New 4 (9.3%) 2 (4.7%) 0.676
p2 0.501 0.156
Variceal bleeding
Past 7 (16.3%) 6 (14.0%) 0.763
New 6 (14.0%) 7 (16.3%) 0.763
p2 0.763 0.501
SBP
Past 12 (27.9%) 11 (25.6%) 0.808
New 6 (14.0%) 2 (4.7%) 0.265
p2 0.112 0.007
*
Months till SBP 5.0 (3.0  10.0) 9.50 (9.0  10.0) 0.129
Ascites culture
Positive 1/6 (16.7%) 0/2 (0%) 1.000
Negative 5/6 (83.3%) 2/2 (100%)
Hepatorenal syndrome 1 (2.3%) 1 (2.3%) 1.000
Hepatocellular carcinoma 4 (9.3%) 5 (11.6%) 1.000
Death 4 (9.3%) 3 (7.0%) 1.000
SBP: spontaneous bacterial peritonitis. p1: p value for Chi square test for comparing between the two studied groups. p2: p value for Chi square
test for comparing between past and new. Abnormally distributed quantitative data were expressed in Median (Min.  Max.) and were
compared using Mann Whitney test.
* Statistically significant at p 6 0.05.
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patient from the norfloxacin group, and it was positive for
E. coli.
Patients who developed SBP were significantly more likely
to have a past history of previous SBP (p = 0.029), and had
significantly worse overall survival (p < 0.001) compared to
patients who did not develop SBP during the study duration.Significantly higher baseline values for serum bilirubin (3.2;
vs. 2.9 mg/dl; p= 0.007), prothrombin time (17.8 vs. 15.9 s,
p= 0.040) and Child–Pugh score (11.67 vs. 9.75, p = 0.011)
were also found among patients who developed SBP compared
with those who did not, whereas ascitic fluid total protein and
renal function tests were comparable in both. Although 75%
of SBP patients were on norfloxacin vs. 25% on rifaximin,






Age (years) 53.3 ± 7.3 51.7 ± 10.5 0.566
Sex (male) 6 (75.0%) 62 (79.5%) 0.976
Past SBP 5 (62.5%) 18 (23.1%) 0.029*
Child–Pugh class
B 1 (12.5%) 39 (50.0%) 0.081
C 7 (87.5%) 39 (50.0%)
Child score 11.67 ± 1.92 9.75 ± 2.49 0.011*
Serum bilirubin
(mg/dl)
3.2 ± 1.7 2.9 ± 1.2 0.007*
Serum albumin (g/dl) 2.6 ± 0.5 2.9 ± 0.4 0.231
Prothrombin time (sec) 17.8 ± 1.6 15.9 ± 1.9 0.040*
Blood urea nitrogen
(mg/dl)










126.9 ± 7.6 131. ± 5.3 0.407
Ascitic fluid protein
(g/dl)
0.8 ± 0.4 1.1 ± 0.5 0.063
Antimicrobial
Norfloxacin 6 (75.0%) 37 (47.4%) 0.265
Rifaximin 2 (25.0%) 41 (52.6%)
Overall survival
(months)
6.50 ± 2.78 10.59 ± 2.11 <0.001*
SBP: spontaneous bacterial peritonitis. Qualitative data were
expressed using number and percent and compared using Chi
square test. Normally distributed quantitative data were expressed
in (Mean ± SD) and compared using t-student test. Abnormally
distributed quantitative data were expressed in Median (Min. 
Max.) and compared using Mann Whitney test.
* Statistically significant at p 6 0.05.







Compliance 39 (90.7%) 35 (81.4%) 0.213
Months till compliance
failure
9.0 ± 0.82 6.75 ± 1.28 0.010*
Overall survival 25 (58.1%) 25 (58.1%) 1.000
Months till study
endpoint
10.16 ± 2.64 10.26 ± 2.32 0.863
Qualitative data were expressed using number and percent and
compared using Chi square test. Quantitative data were expressed
in (Mean ± SD) and compared using t-student test.
* Statistically significant at p 6 0.05.














Figure 1 Frequency of past and new episodes of spontaneous
bacterial peritonitis.
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icant (p= 0.265), as shown in Table 3.
4.3. Patient’s compliance and drug safety
The rate of adherence to therapy (compliance) was higher with
norfloxacin (90.7%) compared to rifaximin (81.4%), with sta-
tistically nonsignificant difference. Moreover, among the
patients who failed to adhere to the drug regimen, the time
lapse till compliance failure was significantly longer fornorfloxacin versus rifaximin (Table 4, Fig. 2). Most patients
reported a difficulty to adhere to the three times per day-
regimen of rifaximin, while the rest (in both groups) reported
that the problem was financial. The monthly cost for nor-
floxacin regimen was estimated at about 38.50 LE, while that
of rifaximin was about 306 LE.
The most commonly reported adverse effects in the nor-
floxacin group were gastrointestinal (nausea, abdominal
cramps and flatulence; 27.9%), in addition to headache, dizzi-
ness and asthenia (9.3%), while in the rifaximin group the
main adverse effects were gastrointestinal (nausea, vomiting
and abdominal cramps; 25.6%) and generalized weakness or
fatigue (4.7%) with no significant difference of overall fre-
quency between both groups (p= 0.741).
4.4. Overall survival
Patient’s survival was equal for norfloxacin and rifaximin
patients (58.1%, both), as demonstrated in Table 4 and
Kaplan Meier curve in Fig. 3. They also had similar duration
of time lapse till occurrence of one of the study endpoints
(p= 0.863). The death rate was comparable in both groups
(9.3% for norfloxacin vs. 7.0% for rifaximin; Table 1), and
Figure 3 Kaplan Meier curve for overall survival.
224 M.M. Shamseya, M.A. Madkourthe leading causes of death were hepatorenal syndrome, mas-
sive variceal bleeding and hepatic encephalopathy.
5. Discussion
Numerous clinical trials and post-marketing surveillance pro-
grams have clearly proved the antibiotic rifaximin to have an
excellent safety profile, probably due to its negligible absorp-
tion from the gut, and consequently its lack of systemic activ-
ity.32,33 The only few adverse reactions reported were
gastrointestinal (GIT) in nature, such as flatulence and nausea.
Norfloxacin, on the other hand, is readily absorbed from the
gut, which makes it more likely to induce systemic side effects.
GIT effects (such as nausea, vomiting, and diarrhea), as well as
neurological manifestations (such as headache, insomnia,
dizziness and asthenia) are common. Other rare but serious
side effects include tendonopathy, exacerbation of myasthenia
gravis and life threatening arrhythmias.34 In the present work,
both agents showed only mild to moderate, generally tolerated
side effects, with no significant difference between both. Nev-
ertheless, it was challenging to differentiate between the true
side effects of the tested antimicrobials (particularly rifaximin)
and the usual common dyspeptic symptoms of the portal
hypertensive state (caused by gastropathy, enteropathy,
colopathy and cholecystopathy). This issue was similarly
encountered in other studies testing the efficacy of rifaximin
for treatment of hepatic encephalopathy.35–37 The authors
explained that the GIT adverse events – which were frequently
reported in their trials – were not surprising because patients
with advanced liver disease were involved, and that most of
the symptoms were rather due to progression of disease or
complications of cirrhosis. All three studies even stated that
there were no differences in adverse-event profiles between
patients on rifaximin and those on placebo.
The European Association for the Study of the Liver
(EASL) has identified three patient populations at high-risk
for developing SBP: patients with acute gastrointestinal hem-
orrhage; those with low total protein content in ascitic fluid
and no prior history of SBP; and those with a previous history
of SBP.38 In comparison, our patients who developed SBP dur-
ing the study duration were significantly more likely to have
had a history of previous SBP, higher baseline values for serumbilirubin, prothrombin time and Child–Pugh score. As
expected, they also had significantly worse overall survival
compared to patients who did not develop SBP.
Despite the fact that 75% of patients who developed SBP in
our study were on norfloxacin versus 25% on rifaximin, the
difference, however, did not prove to be statistically significant.
Rifaximin patients also developed fewer episodes of SBP and
had longer infection-free periods than those on norfloxacin,
although, again, with no statistically significant difference
between both drugs. Nevertheless, rifaximin significantly
reduced the rate of new compared to past episodes of SBP by
20.9% (p= 0.007) versus 13.9% (p = 0.112) with norfloxacin.
To the best of our knowledge so far, no published studies
are available comparing norfloxacin to rifaximin for SBP pro-
phylaxis. Only one recent study by Lutz et al. prospectively
evaluated 152 ascitic patients for the risk of developing SBP
under the use of antimicrobial prophylaxis with rifaximin ver-
sus the systemically absorbed antibiotic ciprofloxacin.39 It was
a four-week follow-up study, after which they reported a sig-
nificantly lower rate of SBP in patients treated with systemic
antibiotic prophylaxis (n = 17), while SBP rates in patients
with no prophylactic treatment (n= 108) and in patients tak-
ing rifaximin (n= 27) were comparable. They hypothesized
that the higher rate of SBP episodes under rifaximin in com-
parison with ciprofloxacin might be attributed to rifaximin
resistance, or to the fact direct bacterial translocation from
the intestine might not be the only route of infection in SBP
patients. Bacteremia related to poor oral hygiene, for example,
might represent another possible source of SBP which could be
prevented only by the use of a systemic antibiotic. However,
this study is limited by its short duration, small number of
patients, and neglecting to mention the possible long-term sys-
temic side effects of ciprofloxacin, which is known to be more
readily absorbed via oral route (80–100% bioavailable), in
comparison with the limited 30–40% bioavailability of our
tested antimicrobial, norfloxacin.40
On the other hand, few studies have investigated rifaximin
versus placebo for SBP prophylaxis in cirrhotics. A cohort
study by Hanouneh et al. found a transplant-free survival ben-
efit with the use of rifaximin in cirrhotic patients with ascites
and no prior history of SBP than those who didn’t receive
antibiotic prophylaxis.41 Another prospective case-control
study by Danulescu et al. suggested that rifaximin can signifi-
cantly decrease the polymorphonuclear leukocytic count in
ascitic fluid of cirrhotic patients with refractory ascites com-
pared to placebo, with a net improvement of the general
condition.42
Vlachogiannakos et al. also showed that patients who
received rifaximin had a significantly lower risk of developing
variceal bleeding, hepatic encephalopathy (HE), SBP and
hepatorenal syndrome than matched control subjects who
did not receive antibiotic prophylaxis, in addition to signifi-
cantly higher five-year cumulative probability of survival.43
In comparison, our results demonstrated that patients on
rifaximin developed fewer episodes of HE than patients on
norfloxacin (4.7% and 9.3%, respectively). Additionally,
rifaximin was found to reduce the number of new compared
to past episodes of HE by 11.6% versus 4.7% for nor-
floxacin. The difference, however, was not statistically signif-
icant in both occasions. Patient’s survival was also found
equal in both the norfloxacin and rifaximin groups, with
comparable death rates.
Rifaximin: A reasonable alternative for norfloxacin 225Interestingly, patient succeeded to adhere to therapy
slightly better with norfloxacin than rifaximin, and for a signif-
icantly longer time. Most patients reported a difficulty to
adhere to the three times per day-regimen of rifaximin, while
the rest (in both groups) reported that the problem was finan-
cial. The monthly cost for norfloxacin regimen was estimated
at about 38.50 LE, while that of rifaximin was about 306.00
LE, which – of course – points out a great difference in finan-
cial burden between the two drugs (almost eightfold monthly
cost for rifaximin regimen). One of the weaknesses of our
study was – may be – allowing the patients to buy the medica-
tions themselves, which might have reduced their compliance.
On the other hand, it gave us a better hint about the extent of
their ‘‘real” ability to comply with such an expensive drug reg-
imen intended for long-term use, and whether or not they
would be able to afford it later on.
The most important limitation of our study is that it was
not a randomized, placebo controlled trial, but rather a
prospective longitudinal observational study with a relatively
limited sample size. In this type of study, a selection and obser-
ver bias cannot be ruled out completely. However, given the
high mortality of SBP, ethical concerns must be raised against
a randomized controlled trial withholding any form of antimi-
crobial prophylaxis to the placebo group in spite of being can-
didates for prophylaxis according to guidelines.
In conclusion, rifaximin has proved itself to be – at least –
as good as norfloxacin, and seems to be an appropriate antibi-
otic alternative for long-term primary and secondary prophy-
laxis of SBP in cirrhotic patients with ascites with outcomes
comparable to norfloxacin. Financial burden on the patient,
however, remains an issue. Larger randomized controlled trials
are needed to confirm our results, and it should take into
consideration possible modifications of rifaximin dose regimen
to improve patient’s compliance to therapy. Also, follow-up
should continue for a longer period of time to capture any
unidentified long-term adverse effects of the drug, and because
it is up till now uncertain whether prophylaxis in patients with
prior SBP should be continued without interruption until
liver transplantation or death, or whether treatment could be
discontinued in patients showing an improvement of liver
disease.
Conflict of interest
The authors declare that there are no conflicts of interest.
References
1. Caly WR, Strauss E. A prospective study of bacterial infections in
patients with cirrhosis. J Hepatol 1993;18:353–8.
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17. Andreu M, Solá R, Sitges-Serra A, Alia C, Gallen M, Vila MC,
et al. Risk factors for spontaneous bacterial peritonitis. Gastroen-
terology 1993;104:1133–8.
18. Llach J, Rimola A, Navasa M, Ginès P, Salmerón JM, Ginès A,
et al. Incidence and predictive factors of first episode of sponta-
neous bacterial peritonitis in cirrhosis with ascites: relevance of
ascitic fluid protein concentration. Hepatology 1992;16:724–7.
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